Biotech Business – February 17, 2026
The funding comprises a EUR 2 million non-dilutive grant from the European Innovation Council (EIC) Transition program and EUR 3.9 million in private capital and convertibles from Voima Ventures, Nordic Science Investments (NSI), Illumina Ventures, Almi invest, Life Science Invest and several undisclosed private investors from the genomics technology space.
Digital health – February 16, 2026
It is the first AI operating system in Europe to achieve registration in EUDAMED as a medical device, according to the company.
MedTech Business – February 16, 2026
Amferia’s antibacterial wound dressing has been granted approval by the US Food and Drug Administration (FDA) through the De Novo Classification Request track, allowing Amferia to enter the US market with a unique Class 2 medical device antibacterial dressing for advanced wound care.
Agreement – February 16, 2026
Suzhou Ribo Life Science and its Swedish subsidiary Ribocure Pharmaceuticals have entered into an exclusive worldwide licensing agreement with Madrigal Pharmaceuticals for six pre-clinical small interfering RNA (siRNA) programs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Career choice – February 16, 2026
María Bueno Álvez is a final-year PhD student at SciLifeLab and the KTH Royal Institute of Technology. She works in the Human Protein Atlas under the supervision of Professor Mathias Uhlén.
Business article – February 12, 2026
The European Life Sciences Coalition (ELSC) aims to strengthen Europe’s life sciences and biotechnology VC ecosystem by mobilizing greater levels of private and public investment across the sector.
Opinion & debate
Clinical Trials – February 10, 2026
The company has announced six-month data from the 12-month, real-world INFUSE study, evaluating the effectiveness of Vyepti in adults with migraine who had failed at least one preventive anti-calcitonin gene–related peptide (aCGRP) treatment, at any time point previously.
Clinical Trials – February 2, 2026
SynAct Pharma has initiated a Phase 2 study (RESPIRE) with resomelagon in patients hospitalized with respiratory insufficiency due to viral infections.
Clinical Trials – January 27, 2026
The results showed that approximately 30 percent of patients achieved complete skin clearance (PASI 100) at week 16, and that more than half reached almost complete clearance (PASI 90).
Clinical Trials – January 27, 2026
The results show that all patients responded positively to the ODX treatment, with a transition from progressive disease to stable disease.
Clinical Trials – January 12, 2026
Elicera Therapeutics has announced final data from its Phase I/IIa clinical trial evaluating the oncolytic virus ELC-100 in patients with advanced, end-stage neuroendocrine tumors who had exhausted all currently available therapeutic options and having progressing diseases.
Clinical Trials – January 9, 2026
Sobi has announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFNγ)-driven sepsis (IDS), showed proof-of-concept with observed improvement in organ dysfunction and survival.
PharmaRelations
This is a position that combines strategic oversight, business development, and team leadership. The successful candidate will play a pivotal role in shaping our services to our customers.
PharmaRelations
This is a leadership position that combines strategic oversight, business development, and team leadership. The successful candidate will play a pivotal role in shaping our qualtiy assurance services to our customers.
Otsuka Pharma Scandinavia
This is a strategically important, scientifically driven role where immunological expertise supports meaningful progress in a collaborative, people-first, and innovative environment.
PharmaRelations
Are you passionate about Quality Assurance and Regulatory Compliance in the Medical Device Device companies? PharmaRelations is expanding its team of expert consultants, and we are looking for a talented QA/RA Medical Device Consultant to join us!
Conaxess Trade
A high‑impact role where you take ownership of QA across the Nordics and help shape the future of leading self‑care brands. Ready to make your mark?
Confidential
PharmaRelations, together with the Board of Directors, are seeking an experienced and visionary CEO to lead a rapidly growing Life Science company through its next phase of development and growth. The company is based in southern Sweden.
In a new job – February 5, 2026
Gauthy, who has played a central role in building Zelluna’s manufacturing and CMC capabilities since joining in 2022, assumes the role with immediate effect.
In a new job – January 29, 2026
After close to ten years as CEO, Annette Säfholm has decided to step down from her role. The Board of Directors has appointed Julie Waras Brogren as the new Chief Executive Officer.
In a new job – January 28, 2026
“Claus has a strong track record of building and scaling health-focused businesses, combining strategic clarity with deep customer and market insight. His experience across regulated health products, international commercialization, and partnership-driven growth makes him exceptionally well suited to lead Sigrid into its next phase. I would also like to thank Sana Alajmovic for building the […]
Careers article – February 3, 2026
At Elekta’s Strategic Update for investors the company announced that, as a consequence of the company’s new operating model, it is reducing the number of employees by 450.
Careers article – January 15, 2026
A large international study published in The Lancet, suggests that adding just five minutes of moderate-intensity activity per day – or cutting sitting time by 30 minutes – could prevent a substantial share of premature deaths.
Careers article – January 15, 2026
Samuli Ripatti has a background in mathematical statistics but his research has always been focused on applying and developing biostatistical methods to address scientific questions in medical and population genetics.
Profiles in Business – December 8, 2025
Successful businessman and former chairman of AstraZeneca, Leif Johansson, has accumulated vast experience and knowledge about international competition, leadership, business development, and entrepreneurship, not least when it comes to science-driven industries like the life science industry.
Nobel Prize 2025 – November 25, 2025
With a family legacy in medicine dating back to the Shogun era, the Japanese immunologist Dr. Shimon Sakaguchi has dedicated his career to the science. A 30-year-old pivotal discovery led him to this year’s Nobel Prize in Physiology or Medicine for research in peripheral immune tolerance.
Nobel Prize 2025 – November 25, 2025
Nobel Prize laureate Mary E. Brunkow’s career path has shifted between industry and academia but her end goal to generate clinical benefit and her passion for exploring new areas have never wavered.

Legal Advice article – February 10, 2026
On 9 February 2026, Novo Nordisk announced it has filed a lawsuit against U.S. telehealth company Hims & Hers, alleging that the firm is offering compounded, non‑FDA‑approved versions of Wegovy and Ozempic that could put patients at risk.
Biotech Business – February 4, 2026
Cereno Scientific is broadening the development focus of its HDAC inhibitor CS014 to pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Agreement – January 30, 2026
Bavarian Nordic has announced an agreement with Eurofarma, granting them exclusive rights to sell and distribute Bavarian Nordic’s chikungunya vaccine, CHIKV VLP, in Brazil.
Acquisition – February 12, 2026
Devyser Diagnostics has entered into an agreement relating to the acquisition of 100 percent of the shares in Cybergene AB, a Swedish company within the Level Bio group.
Digital health – February 10, 2026
Europe is moving towards a digital future for medicines information, a new report from AESGP, EFPIA and Medicines for Europe shows.
MedTech Business – February 3, 2026
On 10 December 2025, Amplex announced a public offer to the holders of shares and warrants of ADDvise Group. On 27 January 2026, Amplex announced that the offer had been accepted to such extent that Amplex will become the owner of 94.31 per cent of all shares in ADDvise upon settlement of the offer.
Biotech Business – February 11, 2026
The financing round was led by Sciety and the capital will be used to advance the company’s ongoing clinical study and to build the data required for the next stage of its development programme.
Biotech Business – February 9, 2026
Medivir has completed a directed share issue of SEK 45 million (before issue costs) to Carl Bennet AB, issuing 90 million new shares at SEK 0.50 per share—a 19 percent premium to the closing price on February 5, 2026.
Biotech article – February 5, 2026
Denmark’s recent regulatory moves are increasingly described as a competitive advantage for the country’s life science sector, as the government aligns national rules with the EU Pharmaceutical Package and the forthcoming Biotech Act, according to analysis from Pharmadanmark and EU policy commentators.
Science Award – February 12, 2026
This year’s Sjöberg Prize of one million US dollars is awarded to a British cancer researcher who has provided fundamental knowledge about evolution in tumours.
Science News – February 10, 2026
Data from Finnish and Swedish cohorts link specific RAS mutation subtypes to distinct treatment outcomes, strengthening the evidence base for biomarker‑guided therapy.
Science News – February 9, 2026
A 2026 population‑based cohort study covering Denmark, Finland, Iceland, Norway and Sweden analysed 1‑year relative survival and excess mortality in cancer patients diagnosed during March–December 2020 versus expectations from 2011–2019.
Upcoming events
This site uses cookies